

Index

ABANDONMENT

Rule 10b-5, loss causation, **11:9**

ABSTENTION

Generally, **23:3**

ABUSIVE DISCOVERY

Private Securities Litigation Reform Act of 1995, class actions, **3:8 to 3:8.90**

ABUSIVE LITIGATION

Private Securities Litigation Reform Act of 1995, sanctions for, **3:19**

ACCOUNTANTS

Insider trading, liability, **15:23**

ACCOUNTING

Sarbanes-Oxley Act, management assessment of internal accounting controls—Section 404, **5A:14**

AIDING AND ABETTING

Insider trading, Stoneridge decision, **15:9, 15:17**

Rule 10b-5, constitutional law, **9:8**

ANALYSTS

Insider trading, fraud on the market theory in actions against analysts, **15:11**

Rule 10b-5, fraud-on-the-market theory, **10:30.10**

AOL-SIMPSON DECISION

Insider trading, Ninth Circuit, expanding liability of secondary actor, **15:28**

APPRAISAL

Interference with market for corporate control, **16:8**

APPROVAL

Class actions, judicial approval of settlement, **25:3**

ARBITRATION

Racketeer influenced and corrupt organizations, **22:12 to 22:14**

ARRANGEMENTS

Monitoring, institutional investors, **25:1.30**

Pay to play, selection of interim lead plaintiff, **25:1.20**

ARTIFICIAL INFLATION

Rule 10b-5, fraud on the market and, **11:11**

ASSIGNMENT

Section 10(b) claims, **26:1, 26:2**

AT LEAST AS LIKELY STANDARD

Supreme Court, pleading requirements for PLS., **3:11.70, 3:11.80**

ATTORNEY-CLIENT PRIVILEGE

Sarbanes-Oxley Act, securities fraud, new statutory duty to disclose client confidences, **5C:3, 5C:5**

ATTORNEYS

Fees. See **Attorneys' Fees** (this index)

Insider trading, liability, **15:24**

Non-lead counsel, issues with and other actors seeking payment from the common fund, **25:4.40**

Private Securities Litigation Reform Act of 1995, sanctions, **3:19**

Sarbanes-Oxley Act (SOX) (this index)

ATTORNEYS' FEES

Generally, **21:1, 21:2**

Class actions, **25:4 to 25:4.30**

Lodestar versus percentage-of-fund recovery in class action, **25:4.10**

Objecting to attorneys' fees, **25:4.20**

Presumption of reasonableness to agreed-upon fees in class action, **25:4.30**

Racketeer influenced and corrupt organizations, **22:9**

AUCTIONING

Class actions, selection of class counsel through auctioning, **25:6, 25:8**

AUDITS AND AUDITORS

Pleading scienter for outside auditors, **24:5**

Sarbanes-Oxley Act (SOX) (this index)

AUTOMATIC STAY

Sarbanes-Oxley Act of 2002, debtor-company in bankruptcy, **5D:3**

AWARENESS OF PLAINTIFF

Insider trading, Stoneridge decision, **15:16 to 15:20**

BALANCE OF INTERESTS TEST

International securities regulation, **27:5**

BANKRUPTCY AND SECURITIES FRAUD

Sarbanes-Oxley Act (SOX) (this index)

BARS

Sarbanes-Oxley Act, officer and director bars—Section 305, **5A:10**

BENEFIT OF THE BARGAIN

Instructions to jury, Section 10(b) of Securities Exchange Act of 1934, **24:47**
 Rule 10b-5, **13:3, 14:65**

BROKERS

Implied actions and remedies, Section 15 of Securities Exchange Act of 1934, **19:8**

CAUSATION

Instructions to jury, Section 10(b) of Securities Exchange Act of 1934, **24:45**

Loss causation. See **Private Securities Litigation Reform Act of 1995** (this index)

Proxy fraud. See **Proxy Fraud** (this index)
 Rule 10b-5. See **Rule 10b-5** (this index)
 Section 11, Securities Act of 1933, **6:25**
 Securities Exchange Act of 1934, **8:4, 8:16**

CEO

Sarbanes-Oxley Act, certification requirements, **5A:3, 5B:4**

CERTIFICATION

Barrier to class certification, **24:15**

Class actions

generally, **24:13**

barrier, **24:15**

loss causation, **24:13.20**

materiality, **24:13.10**

Sarbanes-Oxley Act (SOX) (this index)

CFO

Sarbanes-Oxley Act, certification requirements, **5A:3, 5B:4**

CHALLENGES

Event studies in securities fraud litigation, **25B:5**

CHARTS

Instructions to jury, **24:26, 24:27**

CHURNING

Insider trading. See **Insider Trading** (this index)

CIVIL ACTIONS

Sarbanes-Oxley Act enhancement of private civil liability. See **Sarbanes-Oxley Act (SOX)** (this index)

CLASS ACTION FAIRNESS ACT

Generally, **25A:1**

CLASS ACTIONS

Generally, **25:1 et seq.**

Advertising investigations, solicit lead plaintiffs, **25:1.40**

Attorneys' fees, **25:4 to 25:4.30**

Auctioning, selection of class counsel through, **25:6, 25:8**

Bankruptcy and securities fraud, **5D:4**

CLASS ACTIONS—Cont'd

Barrier to class certification, **24:15**

Certification of class

generally, **11A:17 et seq., 24:13**

barrier, **24:15**

loss causation, **24:13.20**

materiality, **24:13.10**

mismatch defense, **24:13.30**

Morrison case, effect on, **25:9**

rebutting reliance, **24:13.30**

reliance, rebutting, **24:13.30**

Class Action Fairness Act, **25A:1**

Counsel, selection of, **25:6**

Cy Pres awards, **25:3.20**

Fraud-on-the-theory, **11A:17.10, 11A:17.20**

Independent approval of settlement, **25:3.10**

Judicial approval of settlement, **25:3**

Lead plaintiff, selection of, **25:1 et seq.**

Lodestar attorney fees versus percentage-of-fund recovery in class action, **25:4.10**

Materiality, plausible allegation, **11A:17.40**

Monitoring arrangements, institutional investors, **25:1.30**

Non-lead counsel, issues with and other actors seeking payment from the common fund, **25:4.40**

Objecting to attorneys' fees, **25:4.20**

Pay to play arrangements, **25:1.20**

Presumptions

reasonableness to agreed-upon fees, **25:4.30**
 reliance, rebutting presumption, **11A:17.40**

Private Securities Litigation Reform Act of 1995. See **Private Securities Litigation Reform Act of 1995** (this index)

Publication of settlement, **25:2**

Rebutting

fraud-on-the-theory, **11A:17.10**
 reliance, presumption of, **11A:17.40**

Reliance, rebutting presumption, **11A:17.40**

Rule 10b-5, rebuttal of fraud-on-the-market theory, class certification, **10:30.15**

Sarbanes-Oxley Act (SOX), **5D:4**

Securities Litigation Uniform Standards Act of 1998

actions that are joined, consolidated, or otherwise proceed as a single action, **5:6.50**

defined class actions, **5:6**

state court, federal class actions in, **5:8.70**

Security for costs, **25:5**

Selection of counsel, **25:6**

Selection of interim lead plaintiff

advertising investigations, solicit lead plaintiffs, **25:1.40**

monitoring arrangements, institutional investors, **25:1.30**

CLASS ACTIONS—Cont'd

Selection of interim lead plaintiff—Cont'd
 Pay to play arrangements, **25:1.20**
 Settlement, **25:2, 25:3, 25:3.10**
 Third Circuit task force, recommendations, **25:7**

COLLECTIVE SCIENTER

Tellabs case, **24:55**

COMMON LAW

Loss causation, common law fraud, **11A:20**
 Rule 10b-5. See **Rule 10b-5** (this index)
 Sarbanes-Oxley Act, attorneys duty to blow
 whistle on securities fraud, **5C:2**
 Section 11, Securities Act of 1933, **6:7**

COMMON SECONDARY ACTORS

Insider trading, Stoneridge decision, **15:18**

COMPENSATION

Forfeiture of executive compensation upon
 restatements—Section 304, **5A:9**

CONDOMINIUMS

Investment contracts, **1:6**

CONDUCT OR MISCONDUCT

Sarbanes-Oxley Act, conduct rules for
 attorneys—Section 307, **5A:12**

CONDUCT TEST

Internet, extraterritorial subject matter jurisdiction, **28:3, 28:7, 28:8**

CONFIDENTIAL SOURCES

Circuit survey and effect of Tellabs, **24:53.10**
 Discovery, **24:54, 24:54.10**
 Documents from, **24:53.20**
 Pleading after Tellabs, **24:52.50, 24:53, 24:55**
 Private investigators, **24:53.30**
 Rule 26 discoverability of identities, **24:54.10**

CONFIDENTIAL WITNESSES

Securities fraud pleading, **24:53**

CONFLICT OF LAWS

Sarbanes-Oxley Act, state attorney confidentiality
 standards in conflict with SEC regime, **5C:5**

CONGRESSIONAL INTENT

Private Securities Litigation Reform Act of 1995,
 loss causation, **11A:4**

CONSENT

Class actions, approval of settlement, **25:3,**
25:3.10

CONSEQUENTIAL DAMAGES

Rule 10b-5. See **Rule 10b-5** (this index)

CONSTITUTIONAL LAW

Event studies in securities fraud litigation, **25B:2**
 Rule 10b-5. See **Rule 10b-5** (this index)

CONSTRUCTION AND INTERPRETATION

Private Securities Litigation Reform Act of 1995 (this index)

CONSUMER FINANCIAL PROTECTION BUREAU

Dodd-Frank, **5E:4**

CONTRACT VOIDANCE

Generally, **23:6**

CONTRIBUTION AND INDEMNIFICATION

Generally, **20:1 et seq.**
 Basics of D&O insurance, **20:29**
 Claim procedure, **20:8**
 Common provisions in D&O insurance, **20:30**
 Director and officer (D&O) insurance and securities fraud
 basics of D&O policy, **20:29**
 common provisions, **20:30**
 settlement, **20:32**
 tower, **20:31**

Implied right to contribution. See **Rule 10b-5** (this index)

Insurance

generally, **20:28**
 basics of D&O insurance, **20:29**
 director and officer (D&O) insurance and securities fraud, above
 fraud by directors and officers, **20:29**
 Joint tortfeasors, **20:4**
 Judicial power to create, **20:3**
 Rule 10b-5. See **Rule 10b-5** (this index)
 Settlement
 D&O insurance, **20:32**
 effect on contribution, **20:5, 20:27**
 Tower, D&O insurance, **20:31**

CORNERSTONE RESEARCH

Class actions under PSLRA, statistics, **4:3**

CORPORATE FINANCE THEORY

Private Securities Litigation Reform Act of 1995,
 loss causation, **11A:8**

CORPORATE OFFICERS AND DIRECTORS

Insider trading, liability, **15:25**

COSTS AND EXPENSES

Generally, **21:1, 21:2**
 Attorneys' fees. See **Attorneys' Fees** (this index)
 Class actions, security for costs, **25:5**
 Racketeer influenced and corrupt organizations,
22:9
 Section 16, Securities Exchange Act of 1934,
8:13

COVER

Rule 10b-5, Tenth Circuit, **14:52**

CREDIT DEFAULT SWAPSFINFA rules, **26A:1****CRIMINAL LAW**Sarbanes-Oxley Act, reliance on criminal law,
5A:25**CRYPTOCURRENCIES**Regulation of, **2:6****CY PRES AWARDS**Class actions, **25:3.20****DAMAGES, LAW OF**Generally, **1:2, 29:1, 29:2**For detailed matters, see more specific entries
throughout this indexSecurities litigation, **1:4****DAMAGES FORMULA**Private Securities Litigation Reform Act of 1995,
3:14.30 to 3:14.50**DAMAGES FOR VIOLATIONS OF SECTION
12, SECURITIES ACT OF 1933**Conduct prohibited by section 12(a)(1), **7:5**Conduct prohibited by section 12(a)(2), **7:6**
a prospectus and the public offering limitation,
7:7Contribution and indemnification, **7:15**Introduction to damages under section 12, **7:9-**
7:13Introduction to damages under section 12 contri-
bution and indemnification, **7:14**Introduction to express remedies, **7:1**Sellers under section 12 and persons liable, **7:2**
those who pass title, **7:3**those who successfully solicit, **7:4**Statutes of limitations for section 12(a)(2), **7:16**Timeliness bars applicable to section 12 claims,
7:8**DEALERS**Implied actions and remedies, Section 15 of
Securities Exchange Act of 1934, **19:8****DECEPTIVE CONDUCT PLUS PLAINTIFF
AWARENESS**Insider trading, Stoneridge decision, **15:16 to**
15:20**DEFENSES**Section 11, Securities Act of 1933, **6:4****DEFINITION**Security, **1:5****DEPOSITIONS**Expert witnesses, **24:23, 24:24**Instructions to jury, **24:28****DIRECT MARKET REPERCUSSION****THEORY**Rule 10b-5, Second Circuit, **14:10****DIRECTOR AND OFFICER (D&O)
INSURANCE**Ancillary sources of damages, **20:29 et seq.****DISCIPLINE**Implied actions and remedies, Section 6(b) of
Securities Exchange Act of 1934, **19:3****DISCLOSURE**Duty, materiality, **10:27.60**Implied actions and remedies, Sections 11(d)(2)
and 17(a) of Securities Exchange Act of
1934, **19:5****Sarbanes-Oxley Act (SOX)** (this index)**DISCOVERY**Generally, **24:16**Depositions. See **Depositions** (this index)Expert witnesses, **24:22 to 24:24**Securities Litigation Uniform Standards Act of
1998, stay, **5:13**Tellabs case, **24:53****DISGORGEMENT**Rule 10b-5. See **Rule 10b-5** (this index)**DIVIDENDS**Section 16, Securities Exchange Act of 1934,
8:11**DODD-FRANK ACT (2010)**Generally, **5E:1 to 5E:5**Antifraud measures, security-based swaps, **5E:2**Consumer financial protection bureau, **5E:4**Extraterritoriality of securities fraud litigation,
5E:5Security-based swaps, antifraud measures, **5E:2**Whistleblowers, **5E:3****DUAL INQUIRY TEST**Ninth Circuit, pleading scienter after Tellabs,
3:11.130**DURA PHARMACEUTICALS CASE****Private Securities Litigation Reform Act of
1995** (this index)**DUTY TO DISCLOSE**Materiality, rule 10b-5, **10:27.60****ECONOMIC LOSS**Private Securities Litigation Reform Act of 1995,
loss causation, **11A:7, 11A:8****EFFECTS TEST**Internet, extraterritorial subject matter jurisdic-
tion, **28:4, 28:7, 28:8**

ELECTION

Rule 10b-5, rescission or rescissionary damages, **14:51**

ELECTRONIC DELIVERY

Federal securities regulation, **5:14**

EMPLOYEE STOCK OPTIONS

Section 16, Securities Exchange Act of 1934, **8:10**

ENFORCEMENT OF SECURITIES LAWS

FINRA and role of SROs, **26A:2**

ENRON SCANDAL

Insider trading, Stoneridge decision, **15:20**

Private Securities Litigation Reform Act of 1995, laxity, **4:4**

EQUITABLE RELIEF

Racketeer influenced and corrupt organizations, **22:9**

ETHICS CODE

Sarbanes-Oxley Act, ethics code for financial officers—Section 406, **5A:15**

EVENT STUDIES IN SECURITIES FRAUD LITIGATION

Generally, **25B:1**

Accounting for tangle of factors, **25B:4**

Acknowledgment of tangle of factors, **25B:4**

Analysis methodology, **25B:3**

Challenging reliability, **25B:5**

Class certification, **25B:6**

Constitutional law, **25B:2**

Dispositive role, Seventh Amendment, **25B:2**

Efficiency of market, **25B:7**

Impact of market, **25B:7**

Loss causation, **11A:16**

Market efficiency, **25B:7**

Market impact, **25B:7**

Methodology, **25B:3**

Potential Seventh Amendment problems, **25B:2**

Questions of market impact and efficiency, **25B:7**

Recognition of tangle of factors, **25B:4**

Reliability challenge, **25B:5**

Rule 10b-5 claims, **25B:6**

Section 10(b) of Securities Exchange Act, **25B:6**

Section 11 of Securities Act of 1933, **25B:8**

Seventh Amendment problems, **25B:2**

Summary judgment, **25B:9**

Tangle of factors, **25B:4**

EVIDENCE

Loss causation, proving, **3:12.10, 11A:16**

EXHIBITS

Instructions to jury, **24:26, 24:27**

EXPENSES

Costs and expenses. See **Costs and Expenses** (this index)

EXPERT WITNESSES

Generally, **24:19 et seq.**

Complaints, **24:2.50**

Depositions, **24:23, 24:24**

Disclosure, **24:22 to 24:24**

Instructions to jury, **24:29, 24:30**

Loss causation, **11A:16**

Private Securities Litigation Reform Act of 1995, damages formula, **3:14.50**

Types of experts, **24:21**

EXTENSION OF CREDIT

Implied actions and remedies. See **Implied Actions and Remedies** (this index)

EXTERNAL MARKET FORCES

Rule 10b-5, Seventh Circuit, **14:39**

EXTRATERRITORIAL JURISDICTION

Dodd-Frank, **5E:5**

International securities regulation. See

International Securities Regulation (this index)

FAIR SHARE RULE

Private Securities Litigation Reform Act of 1995, proportionate liability, **3:14**

FIDUCIARY DUTY

Rule 10b-5, **10:7**

FILING

Implied actions and remedies, Section 13(a) of Securities Exchange Act of 1934, **19:7**

Private Securities Litigation Reform Act of 1965, NERA and cornerstone research securities, **4:3**

FINANCIAL EXPERTS

Sarbanes-Oxley Act, audit committee financial experts—Section 407, **5A:16**

FINANCIAL INDUSTRY REGULATORY AUTHORITY (FINRA)

See **FINRA** (this index)

FINANCIAL OFFICERS

Sarbanes-Oxley Act, ethics code—Section 406, **5A:15**

SROs, role in enforcing securities laws, **26A:2**

FINRA

Claims involving FINRA members, **26A:1, 26A:2**

Credit default swaps under FINRA rules, **26A:1**

Customers and credit default swaps under FINRA rules, **26A:1**

FORCED SALE

Sarbanes-Oxley Act of 2002, bankruptcy and securities fraud, **5D:2**

FORCED SELLER DOCTRINE

Material misrepresentations, Section 11 and Section 12 claims, **14A:2**

FOREIGN CUBED CASES

Rule 10b-5, extraterritorial application, **10:2.50, 10:2.60**

FORFEITURES

Sarbanes-Oxley Act of 2002, forfeiture of executive payments upon restatements—Section 304, **5A:9**

FORMULA FOR DAMAGES

Section 11, Securities Act of 1933. See **Section 11, Securities Act of 1933** (this index)

FRAUD

Confidential witnesses, securities fraud pleading, **24:53**

Event studies. See **Event Studies in Securities Fraud Litigation** (this index)

Insider trading, Stoneridge decision, **15:13, 15:16 to 15:20**

Proxy fraud. See **Proxy Fraud** (this index)

Section 11, Securities Act of 1933, fraud against mutual funds, **6:4.10**

Securities fraud, generally. **Sarbanes-Oxley Act (SOX)** (this index)

FRAUD BY HINDSIGHT

Tellabs case, **24:57**

FRAUD-CREATED-THE-MARKET THEORY

Rule 10b-5, **10:30, 10:31 et seq.**

FRAUD ON THE MARKET

Analysts, actions against, **15:11**

Artificial inflation, Rule 10b-5, **11:11**

Endorsement by Supreme Court, **13:17**

Insider trading, **15:10, 15:11**

Loss causation, **11A:9, 11A:15.10**

Measure of damages, uniformity, **13:16**

Private Securities Litigation Reform Act of 1995, limitation of scope in Dura Pharmaceuticals court decision, **11A:9**

Rule 10b-5, **10:30.10, 10:30.15, 10:30.50, 11:11, 13:16**

Stoneridge decision, **15:10**

GLOSSARY

Generally, **App 4**

GOOD WILL

Section 11 and Section 12, Securities Act of 1933, misrepresentation in registration statements, **14A:1**

GROUP PLEADING

Tellabs, **24:55**

IMPLIED ACTIONS AND REMEDIES

Generally, **19:1 et seq.**

Brokers and dealers, Section 15 of Securities Exchange Act of 1934, **19:8**

Discipline of members, Section 6(b) of Securities Exchange Act of 1934, **19:3**

Disclosure requirements, Sections 11(d)(2) and 17(a) of Securities Exchange Act of 1934, **19:5**

Extension of credit

Rule 10b-16, **19:10**

Section 7(c) of Securities Exchange Act of 1934, **19:4**

Filing requirements, Section 13(a) of Securities Exchange Act of 1934, **19:7**

Obstruction of filings, Section 20(c) of Securities Exchange Act of 1934, **19:9**

Reporting requirements, Section 12(b) and (f) of Securities Exchange Act of 1934, **19:6**

Rule 10b-5. See **Rule 10b-5** (this index)

Section 17(a), **19:1, 19:2**

INDEMNIFICATION

Contribution and indemnification. See **Contribution and Indemnification** (this index)

INFERENCES

Tellabs case, scienter, **24:56 et seq.**

INFORMANTS

Sarbanes-Oxley Act, no retaliation against informants—Section 1107, **5A:21**

INITIAL COIN OFFERINGS

Regulation of, **2:6**

INJUNCTIONS

Generally, **23:2**

Interference with market for corporate control, tender offers, **16:4**

IN LIMINE MOTIONS

Generally, **24:18**

IN RE CHARTER COMMUNICATIONS

Insider trading, Eighth Circuit, **15:27**

INSIDER TRADING

Generally, **15:1 et seq.**

Accountant liability, **15:23**

Analysts, actions against, **15:11**

Attorney liability, **15:24**

Central Bank decision, **15:32**

Churning, **15:4**

Common secondary actors, **15:18**

Congressional restatement of scheme / secondary liability, **15:30**

Corporate officer liability, **15:25**

INSIDER TRADING—Cont'd

Creationism test for scheme / secondary liability, **15:31**
 Deceptive conduct plus plaintiff awareness, **15:16 to 15:20**
 Drafting materials used to effect fraudulent transactions, attorney liability, **15:24**
 Duty to disclose, absence of, **15:3**
 Eighth Circuit, In Re Charter Communications decision, **15:27**
 Fifth Circuit
 pleading scienter after Tellabs, **15:10, 24:10**
 secondary liability issue, **15:29**
 First Circuit, pleading scienter after Tellabs, **24:8**
 Fraud on the market, **15:10, 15:11**
 Implied private rights of action under Section 10(b), **15:12**
 Janus decision, **15:32**
 Lorenzo decision, **15:32**
 Loss causation, pleading, **24:15**
 Misrepresentation or omission in audit opinions, accountant liability, **15:23**
 Ninth Circuit, AOL-Simpson decision, expanding liability of secondary actor, **15:28**
 Outside counsel liability, **15:24**
 Primary liability after Stoneridge decision, **15:22**
 Professional liability under Sarbanes-Oxley, **15:6**
 Reaffirming bar on aiding and abetting liability, **15:9**
 Reliance, **15:10**
 Reviewing materials used to effect fraudulent transactions, attorney liability, **15:24**
 Revising materials used to effect fraudulent transactions, attorney liability, **15:24**
 Sarbanes-Oxley. See **Sarbanes-Oxley Act (SOX)** (this index)
 Scheme / secondary liability, **15:30, 15:31**
Scienter (this index)
 SEC aiding and abetting enforcement actions, **15:17**
 Secondary liability, **15:5, 15:9**
 Secondary liability issue
 Eighth Circuit, In Re Charter Communications decision, **15:27**
 Fifth Circuit, **15:29**
 Ninth Circuit, AOL-Simpson decision, **15:28**
 scheme / secondary liability, **15:30 to 15:32**
 Stoneridge decision, below
 Supreme Court, **15:7 et seq.**
 Seventh Circuit, pleading scienter after Tellabs, **24:11**
 State court litigation, **15:19**
 Stoneridge decision
 generally, **15:7**
 aiding and abetting liability, **15:9**
 analysis of impact, **15:14, 15:15**

INSIDER TRADING—Cont'd

Stoneridge decision—Cont'd
 Central Bank decision, **15:32**
 common secondary actors, **15:18**
 deceptive conduct plus plaintiff awareness, **15:16 to 15:20**
 Enron litigation, **15:20**
 factual background, **15:8**
 fraud on the market, **15:10**
 implied private rights of action under Section 10(b), **15:12**
 Janus decision, **15:32**
 Lorenzo decision, **15:32**
 policy implications in securities fraud action, **15:13**
 primary liability following decision, **15:22**
 reaffirming bar on aiding and abetting liability, **15:9**
 reliance, **15:10**
 SEC aiding and abetting enforcement actions, **15:17**
 secondary actor liability, **15:9**
 secondary liability, generally, **15:7 et seq.**
 state court litigation, **15:19**
 Supreme Court
 Central Bank decision, **15:26, 15:32**
 Janus decision, **15:32**
 Lorenzo decision, **15:32**
 secondary liability guidance. Stoneridge decision, above
 Stoneridge decision, **15:32**
 Third Circuit, pleading scienter after Tellabs, **24:9**

INSTITUTIONAL INVESTORS

Private Securities Litigation Reform Act of 1995, class actions, **3:3, 3:6**
 Selection of an interim lead plaintiff, monitoring arrangements, **25:1.30**

INSTRUCTIONS TO JURY

Generally, **24:25 et seq.**
 Benefit of the bargain, Section 10(b) of Securities Exchange Act of 1934, **24:47**
 Causation, Section 10(b) of Securities Exchange Act of 1934, **24:45**
 Charts and summary exhibits, **24:26, 24:27**
 Conflicting expert testimony, **24:30**
 Damages; caution against inference from instruction, **24:31**
 Depositions, **24:28**
 Expert witnesses, **24:29, 24:30**
 Joint and several liability, **24:34**
 Materiality, **24:50**
 Multiple defendants, caution against, **24:33**
 Multiple recovery, caution against, **24:32**

INSTRUCTIONS TO JURY—Cont'd

- Rescissionary measure, Section 10(b) of Securities Exchange Act of 1934, **24:48**
- Section 10(b) of Securities Exchange Act of 1934 generally, **24:46 et seq.**
- benefit of the bargain measure, **24:47**
- causation, **24:45**
- general measure, **24:46**
- rescissionary measure, **24:48**
- uniform instruction, **24:49**
- Section 11, Securities Act of 1933. See **Section 11, Securities Act of 1933** (this index)
- Section 12, Securities Act of 1933, **24:42 to 24:44**
- Uniform instruction, Section 10(b) of Securities Exchange Act of 1934, **24:49**

INSURANCE

- See **Contribution and Indemnification** (this index)

INTEREST

- Generally, **21:1, 21:3**
- Section 16, Securities Exchange Act of 1934, **8:12**

INTERFERENCE WITH MARKET FOR CORPORATE CONTROL

- Generally, **16:1 et seq.**
- Appraisal remedies, **16:8**
- Federal and state law remedies, relationship between, **16:7**
- Injunctions, tender offers, **16:4**
- Minority shareholders, remedies of, **16:6**
- Proxy solicitation relief, **16:2**
- Rescission, **16:5**
- Tender offers, **16:3, 16:4**

INTERIM LEAD PLAINTIFF

- Selection
 - monitoring arrangements, institutional investors, **25:1.30**
- Pay to play arrangements, **25:1.20**

INTERNATIONAL SECURITIES REGULATION

- Generally, **27:1 et seq.**
- Balance of interests test, **27:5**
- Congressional response to Morrison decision, **10:2.60**
- Criticisms of extraterritorial jurisdiction, **27:1 to 27:6**
- Extraterritorial jurisdiction, **27:1 et seq.**
- Injury to United States, **27:6**
- Legislative intent, **27:3, 27:7**
- Morrison, evolution of and extraterritorial reach of Rule 10b-5, **10:2.70**
- Reliance on international law, **27:4, 27:8**

INTERNATIONAL SECURITIES REGULATION—Cont'd

- Rule 10b-5, application by Second Circuit, **10:2.50, 27:10**
- Statutory construction, **27:3, 27:7**

INTERNET

- Generally, **5:14, 5:15, 28:1 et seq.**
- Conduct test, extraterritorial subject matter jurisdiction, **28:3, 28:7, 28:8**
- Cryptocurrencies, regulation of, **2:6**
- Cyberspace securities transactions, **28:6**
- Effects test, extraterritorial subject matter jurisdiction, **28:4, 28:7, 28:8**
- Extraterritorial subject matter jurisdiction, **28:2 to 28:4**
- Initial coin offerings, regulation of, **2:6**
- Jurisdiction, **28:1 et seq.**
- Personal jurisdiction, **28:5**

INTRODUCTION

- Generally, **1:1 et seq.**

INVESTMENT CONTRACTS

- Condominiums, **1:6**

JOINT AND SEVERAL LIABILITY

- Private Securities Litigation Reform Act of 1995, **3:14.10**

JOINT TORTFEASORS

- Contribution and indemnification, **20:4**
- Instructions to jury, **24:34**

JURISDICTION

- Internet. See **Internet** (this index)
- Securities laws, **1:3.10**

JURY INSTRUCTIONS

- Instructions to jury. See **Instructions to Jury** (this index)

LANGUAGE

- Private Securities Litigation Reform Act of 1995, Supreme Court interpretation of language in Act, **11A:2**

LAXITY

- Enron scandal, Private Securities Litigation Reform Act, **4:4**

LEGISLATIVE HISTORY

- Private Securities Litigation Reform Act of 1995, loss causation, **11A:3**

LIABILITIES

- Securities Act of 1993
 - section 11 liability, elements, **6:3**

LIMITATION OF ACTIONS

- Rule 10b-5, **9:14 et seq.**

LIMITATION OF ACTIONS—Cont'd

Sarbanes-Oxley Act. See **Sarbanes-Oxley Act (SOX)** (this index)
Section 10(b), Securities Exchange Act of 1934, **9:18**
Section 16, Securities Exchange Act of 1934, **8:14.50**

LIMITED LIABILITY COMPANIES

Generally, **2:1 et seq.**
Attributes, **2:3, 2:4**
Predictability, **2:5**
Supreme Court standards for defining security, **2:2, 2:4**

LITIGATION

Generally, **24:1 et seq.**
Artificially inflating the value of a security, **24:3.10**
Investigating and preparing for securities litigation, **24:1.10**
accessing internal company information, **24:1.30**
examining publicly available material, **24:1.20**
The dissipation of that artificial inflation, **24:3.20**
inflationary loss as a result of the company collapse, **24:3.50**
inflationary loss through market forces, **24:3.40**
inflationary loss upon a corrective disclosure and a drop in stock value, **24:3.30**

LOAN LOSS RESERVES

Section 11 and Section 12, Securities Act of 1933, material misrepresentation in registration statements, **14A:1**

LOANS

Sarbanes-Oxley Act, prohibition on loans to executive officers and directors, **5A:6**

LOSS CAUSATION

Insider trading, pleading, **24:15**
Pleading and proving, **24:12**
Private Securities Litigation Reform Act of 1995 (this index)
Rule 10b-5. See **Rule 10b-5** (this index)
Short selling and securities litigation, **24:12.10**

MANAGEMENT

Sarbanes-Oxley Act, management assessment of internal accounting controls—Section 404, **5A:14**

MARKET IMPACT AND EFFICIENCY

Event studies in securities fraud litigation, **25B:7**

MARKET MANIPULATION

Listed stock manipulations, **8:3 to 8:5**
Rule 10b-5, auction rate securities, **10:31.90**

MATERIALITY

Generally, **18:1 et seq.**
Class actions, plausible allegation, **11A:17.40**
Class certification, **24:13.10**
Instructions to jury, **24:50**
Private Securities Litigation Reform Act of 1995, **3:9**
Rule 10b-5. See **Rule 10b-5** (this index)
Soft information, **18:3**
Subjective vs. objective falsehoods, **18:4**
Supreme Court and statistical significance, **18:5**
Supreme Court definition, **18:2**
Virginia Bankshares, **18:3**

MATERIALIZATION OF RISK THEORY

Loss causation, **11A:15.20**

MERITLESS LITIGATION

Private Securities Litigation Reform Act of 1995, sanctions, **3:19**

METHODOLOGY

Event studies in securities fraud litigation, **25B:3**

MINORITY SHAREHOLDERS

Interference with market for corporate control, **16:6**

MISAPPROPRIATION

Rule 10b-5, **10:11**

MISREPRESENTATION

Section 11 and Section 12, Securities Act of 1933, good will and loan loss reserves misrepresented in registration statements, **14A:1**

MODEL COMPLAINT UNDER PSLRA

Generally, **3:20, 3:21**

MONITORING ARRANGEMENTS

Selection of an interim lead plaintiff, institutional investors, **25:1.30**

MOTIONS IN LIMINE

Generally, **24:18**

MOTIVE

Pleading scienter after Tellabs, independent method to establish scienter, **3:11.120**

MULTIDISTRICT TRANSFERS

Pretrial, **24:51**

MULTIPLE DEFENDANTS

Instructions to jury, **24:33**

MULTIPLE RECOVERY

Instructions to jury, **24:32**

MUTUAL FUNDS

Section 11, Securities Act of 1933, **6:4.10**

NATIONAL ECONOMIC RESEARCH ASSOCIATES

Class actions under PSLRA, statistics, **4:3**

NEGATIVE CAUSATION

Section 11, Securities Act of 1933, **6:28, 6:31**

NERA AND CORNERSTONE RESEARCH

Class actions under PSLRA, statistics, **4:3**

OBSTRUCTION OF FILINGS

Implied actions and remedies, Section 20(c) of
Securities Exchange Act of 1934, **19:9**

OPPORTUNITY

Pleading scienter after Tellabs, independent
method to establish scienter, **3:11.120**

OUT-OF-POCKET

Rule 10b-5, **13:4 to 13:6**

PAY TO PLAY

Arrangements, selection of interim lead plaintiff,
25:1.20

PENSION BLACKOUT PERIODS

Sarbanes-Oxley Act, insider trades during pen-
sion blackout periods—Section 306, **5A:11,
5B:6**

PLAINTIFF

Advertising investigations, solicit lead plaintiffs,
25:1.40

Monitoring arrangements, institutional investors,
25:1.30

Pay to play arrangements, **25:1.20**

PLEADINGS

Generally, **24:2**

Adequate theories of loss, **24:3**

Confidential witness, securities fraud pleadings,
24:53

Experts in complaints, **24:2.50**

Loss theories, **24:3**

Outside auditors, scienter, **24:5**

Private Securities Litigation Reform Act of 1995.
See **Private Securities Litigation Reform
Act of 1995** (this index)

Tellabs case, **24:52.50, 24:53, 24:55**

POSTJUDGMENT INTEREST

Generally, **21:1, 21:3**

PRACTICE

Generally, **24:1 et seq.**

PREEMPTION

Federal securities regulation, generally, **5:1**

Sarbanes-Oxley Act, attorney disclosure require-
ments, new SEC professional standards,
5C:6

PREJUDGMENT INTEREST

Generally, **21:1, 21:3**

PRESUMPTIONS

Attorneys' fees in class action, reasonableness to
agreed-upon fees, **25:4.30**

Reliance, rebutting presumption of in class
action, **11A:17.40**

Rule 10b-5, **10:30**

PRIVATE ACTIONS

Insider trading, Stoneridge decision, **15:12**
Sarbanes-Oxley Act (SOX) (this index)

PRIVATE SECURITIES LITIGATION

REFORM ACT OF 1995

Generally, **3:1 et seq., 4:1 et seq.**

Abusive discovery, class actions, **3:8 to 3:8.90**

Abusive litigation, sanctions for, **3:19**

Allegations, Tellabs case, **3:11.10**

At least as likely standard, pleading requirements,
3:11.70, 3:11.80

Attorney sanctions for pursuing meritless litiga-
tion, **3:19**

Causation of loss. Loss causation, below

Class actions

generally, **3:2 et seq., 4:1 et seq.**

abusive discovery, **3:8 to 3:8.90**

auctioning, selection of class counsel through,
25:6, 25:8

certification, loss causation, **11A:17 et seq.,
11A:18, 24:14, 24:15**

empirical analysis, **4:1 et seq.**

fraud-on-the-market theory, **11A:17.10,
11A:17.20**

grundfest and Perino study, **4:2**

institutional investors, **3:3, 3:6**

loss causation, **11A:17 et seq., 11A:18, 24:14,
24:15**

loss causation and limitation of damages,
3:14.40

materiality, plausible allegation, **11A:17.40**

NERA and cornerstone research securities
statistics, **4:3**

professional and lead plaintiffs, **3:2**

rebutting fraud-on-the-market theory,
11A:17.10

rebutting presumption of reliance, **11A:17.40**

selection of class representative, **3:4**

settlement process, **3:7**

Complaint under PSLRA, model complaint, **3:20,
3:21**

Congressional intent, loss causation, **11A:4**

Construction and interpretation, loss causation.

Loss causation, below

Corporate finance theory, loss causation, **11A:8**

Damages, generally, **3:13**

Damages formula, **3:14.30 to 3:14.50**

PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995—Cont'd

Decision of Supreme Court
 Dura Pharmaceuticals case, consequences, **11A:9 to 11A:12**
 Halliburton case, loss causation and class certification, **11A:17.30**
 Dual inquiry test of Ninth Circuit, pleading scienter after Tellabs, **3:11.130**
 Dura Pharmaceuticals case, generally, **11A:1**
 Economic loss, private securities fraud litigation, **11A:7, 11A:8**
 Eighth Circuit, loss causation, **11A:12.90**
 Eleventh Circuit, loss causation, **11A:12.120**
 Enron scandal and laxity, **4:4**
 Experience with PSLRA in the first 18 months, **3:5 et seq.**
 Fair share rule of proportionate liability, **3:14**
 Federal circuits, uncertain loss causation issues not reached by Court in Dura Pharmaceuticals, **11A:11.1**
 Fifth Circuit, loss causation, **11A:12.60**
 Fourth Circuit, loss causation, **11A:12.50**
 Fraud on the market theory, limitation of scope in Dura Pharmaceuticals court decision, **11A:9**
 Fraud-on-the-market theory, loss causation, **11A:9, 11A:15.10**
 Institutional investors, class actions, **3:3, 3:6**
 Joint and several liability for knowing wrongdoing, **3:14.10**
 Language of PSLRA, Supreme Court interpretation, **11A:2**
 Legislative history, loss causation, **11A:3**
 Likely impact of at least as likely standard, **3:11.80**
 Limitation of scope in Dura Pharmaceuticals court decision, **11A:9**
 Loss causation
 generally, **3:12, 11A:1 et seq.**
 appropriate theories of loss, **11A:15**
 circuit survey, **11A:12.10 to 11A:12.120**
 class certification, **11A:17 et seq., 11A:18, 24:14, 24:15**
 common law fraud, **11A:20**
 congress' carefully designed structure of PSLRA and federal securities laws, **11A:5**
 congressional intent supporting, **11A:4**
 corporate finance theory, **11A:8**
 decision of Court in Dura Pharmaceuticals case, consequences of, **11A:9 to 11A:11**
 Dura Pharmaceuticals case, generally, **11A:1**
 economic loss, private securities fraud litigation, **11A:7, 11A:8**
 Eighth Circuit, **11A:12.90**
 Eleventh Circuit, **11A:12.120**
 event studies, **11A:16**

PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995—Cont'd

Loss causation—Cont'd
 evidence, **3:12.10, 11A:16**
 expert testimony, **11A:16**
 Fifth Circuit, **11A:12.60**
 First Circuit, **11A:12.20**
 Fourth Circuit, **11A:12.50**
 fraud-on-the-market theory, **11A:9, 11A:15.10, 11A:17.10, 11A:17.20**
 language of PSLRA, Supreme Court interpretation, **11A:2**
 legislative history, **11A:3**
 limitation of scope in Dura Pharmaceuticals court decision, **11A:9, 11A:11**
 materialization of risk theory, **11A:15.20**
 Ninth Circuit, **11A:12.100**
 pleading, **3:12.10, 11A:13**
 policy concerns of Supreme Court in Dura Pharmaceuticals case, **11A:6**
 post-Dura Pharmaceuticals decision, **11A:14 et seq.**
 proving, **11A:16**
 proxy fraud, **17:6**
 rebutting fraud-on-the-theory, **11A:17.10**
 regression analyses, **11A:16**
 risk free assurances theory, **11A:15.30**
 SEC actions, **11A:20**
 Second Circuit, **11A:11.1, 11A:12.30**
 Section 11 and Section 12 claims, **11A:19**
 Seventh Circuit, **11A:12.80**
 Sixth Circuit, **11A:12.70**
 standards imposed by Court, satisfying, **11A:10**
 Supreme Court decision, **11A:17.30**
 Supreme Court interpretation, generally, **11A:1 et seq.**
 Tenth Circuit, **11A:12.110**
 theories of loss, **11A:15**
 Third Circuit, **11A:12.40**
 uncertain loss causation issues not reached by Court in Dura Pharmaceuticals, **11A:11 to 11A:11.2**
 Materiality, plausible allegation, **11A:17.40**
 Materialization of risk theory, **11A:15.20**
 Material misstatement or omissions, pleadings, **3:9**
 Meritless litigation, sanctions for, **3:19**
 Model complaint under PSLRA, **3:20, 3:21**
 Motive and opportunity as independent method to establish scienter, **3:11.120**
 Mutual funds, **3:14.70**
 Ninth Circuit
 dual inquiry test, pleading scienter after Tellabs, **3:11.130**
 loss causation, **11A:12.100**

PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995—Cont'd

- Oral statements, safe harbor, **3:17**
- Pleading loss causation under the PSLRA, **11A:13**
- Pleadings
 - generally, **3:9 et seq.**
 - loss causation, above
 - Sciencer, pleading after Tellabs, below
- Policy concerns of Supreme Court in Dura Pharmaceuticals case, **11A:6**
- Post-Dura developments
 - generally, **11A:12**
 - forward looking incentives, **10:29**
 - loss causation after Dura, **11A:14**
 - Section 11 and Section 12 claims, **11A:19**
- Presumption of reliance, rebutting, class actions, **11A:17.40**
- Professional and lead plaintiffs, class actions, **3:2**
- Proportionate liability and trial practice, **3:14.20**
- Proving loss causation, **3:12.10**
- Recklessness as independent method to establish scienter, **3:11.120**
- Regression analyses, loss causation, **11A:16**
- Reliance, rebutting presumption in class action, **11A:17.40**
- Rule 10b-5, forward looking incentives, **10:28**
- Safe harbor, **3:15 to 3:18**
- Sanctions for abusive litigation, **3:19**
- Sciencer, pleading after Tellabs
 - generally, **3:11.100**
 - award of draw to plaintiffs, **3:11.110**
 - draw awarded to plaintiffs, **3:11.110**
 - dual inquiry test of Ninth Circuit, **3:11.130**
 - incorporation by reference, **3:11.152**
 - independent methods to establish scienter, **3:11.120**
 - judicial notice, **3:11.152**
 - motive and opportunity as independent method to establish scienter, **3:11.120**
 - recklessness as independent method to establish scienter, **3:11.120**
- Second Circuit, loss causation
 - circuit survey, **11A:12.30**
 - uncertain loss causation issues not reached by Court in Dura Pharmaceuticals, **11A:11.1**
- Selection of class representative, **3:4**
- Settlement
 - class actions, process, **3:7**
 - NERA and cornerstone research statistics, **4:3**
 - reduction, **3:14.30**
- Seventh Circuit
 - application of PSLRA, **3:11.50**
 - confidential sources approval, **3:11.40**
 - historical context of PSLRA, **3:11.30**
 - loss causation, **11A:12.80**

PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995—Cont'd

- Seventh Circuit—Cont'd
 - opinion, **3:11.20**
 - remand, **3:11.90**
- Sixth Circuit, loss causation, **11A:12.70**
- Standards
 - loss causation, **11A:10**
 - pleadings, **3:11**
- State of mind, pleadings, **3:10**
- Supreme Court
 - competing inferences and at least as likely standard, **3:11.70**
 - interpretation of loss causation. Loss causation, below
 - likely impact of at least as likely standard, **3:11.80**
 - opinion, **3:11.60**
 - Tellabs case, guidance on pleading scienter, **3:11.05**
 - Tellabs case, **3:11.05, 3:11.10**
 - Tenth Circuit, loss causation, **11A:12.110**
 - Theories of loss, loss causation, **11A:15**
 - Third Circuit, loss causation, **11A:12.40**
 - Three step process to determine a liable defendants share of responsibility, **3:14.60**
 - Trial practice, **3:14.20**
 - Written statements, safe harbor, **3:17**

PRIVITY

- Rule 10b-5, Fifth Circuit, **14:25**

PROFITS OF DEFENDANT

- Rule 10b-5. See **Rule 10b-5** (this index)
- Sarbanes-Oxley Act, private action for profits—Section 304

PROPORTIONATE LIABILITY

- Private Securities Litigation Reform Act of 1995, **3:14.20**

PROSPECTUS

- Forced seller doctrine and Section 11 and Section 12 claims, **14A:2**
- Material misrepresentations, Section 11 and Section 12 claims, **14A:1, 14A:2**

PROTECTION ORDER

- Sciencer, **24:54.30**

PROVISIONAL REMEDIES

- Generally, **23:5**

PROXIMATE CAUSE

- Securities frauds historic lack of a purchaser-seller requirement, **22:3**

PROXY FRAUD

- Generally, **17:1 et seq.**
- Hidden agenda in Virginia Bankshares, **17:5**

PROXY FRAUD—Cont'd

History of Section 14(a) actions, **17:2**
Loss causation, **17:6**
Virginia Bankshares, **17:3 to 17:5**

PROXY SOLICITATION

Interference with market for corporate control, **16:2**

PSLRA

Private Securities Litigation Reform Act of 1995.
See **Private Securities Litigation Reform Act of 1995** (this index)

PUBLICATION

Class actions, settlements, **25:2**

PUNITIVE DAMAGES

Racketeer influenced and corrupt organizations, **22:14**
Rule 10b-5, **14:66**

RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS

Generally, **22:1 et seq.**, **App 3**
Arbitration, **22:12 to 22:14**
Attorneys fees, **22:9**
Costs, **22:9**
Equitable relief, **22:9**
Historical use of RICO securities fraud, **22:2**
Measure of damages, **22:5**
Punitive damages, securities arbitration, **22:14**
Securities fraud, **22:1**
Securities frauds historic causation requirement, **22:4**
Securities frauds historic lack of a purchaser-seller requirement, **22:3**
State common law damages, **22:10**
State-law RICO equivalents, **22:8**
State statutory damages, **22:11**
The criminal conviction exception, **22:7**
The PSLRA RICO bar, **22:6**

REAL TIME DISCLOSURES

Sarbanes-Oxley Act, SEC review of disclosures—Section 409, **5A:18**

REASONABLENESS

Attorneys' fees in class action, agreed-upon fees, **25:4.30**

REBUTTAL

Class actions
fraud-on-the-theory, **11A:17.10**
mismatch defense, **24:13.30**
reliance, presumption of, **11A:17.40**, **24:13.30**
Rule 10b-5, rebuttal of fraud-on-the-market theory, **10:30.15**

RECEIVERSHIP

Generally, **23:4**

RECKLESSNESS

Pleading scienter after Tellabs, independent method to establish scienter, **3:11.120**

RELIABILITY

Event studies in securities fraud litigation, **25B:5**

RELIANCE

Class action, rebutting presumption, **11A:17.40**, **24:13.30**
Insider trading, Stoneridge decision, **15:10**
Rule 10b-5, **10:30**, **10:30.50**

REMOVAL

Securities Litigation Uniform Standards Act of 1998, **5:12**

REORGANIZATION

Sarbanes-Oxley Act of 2002, bankruptcy and securities fraud, **5D:2**

REPORTING

Implied actions and remedies, Section 12(b) and (f) of Securities Exchange Act of 1934, **19:6**
Sarbanes-Oxley Act, disclosure reports—Section 401, **5A:13**, **5B:7**

RESCISSON

Instructions to jury, Section 10(b) of Securities Exchange Act of 1934, **24:48**

Interference with market for corporate control, **16:5**

Rule 10b-5. See **Rule 10b-5** (this index)

RESCISSORY REMEDIES

Proxy fraud, **17:6**

RESEARCH

Class actions under PSLRA, statistics, **4:3**

RESERVES

Section 11 and Section 12, Securities Act of 1933, misrepresentation of loan loss reserves in registration statements, **14A:1**

RETALIATION

Informants: Sarbanes-Oxley Act, no retaliation against informants—Section 1107, **5A:21**
Whistleblower protection, Sarbanes-Oxley Act—Section 806, **5A:20**

RETROACTIVITY

Rule 10b-5, **9:16 et seq.**

RICO

Racketeer influenced and corrupt organizations.
See **Racketeer Influenced and Corrupt Organizations** (this index)

RULE 10b-5

Generally, **9:1 et seq., 10:1 et seq., 11:1 et seq., 12:1 et seq., 13:1 et seq., 14:1 et seq.**
 Abandonment of loss causation, **11:9**
 Aiding and abetting, constitutional law, **9:8**
 American Pipe, tolling, **9:20.40**
 Analysis of availability of damages, **12:11**
 Analysts, fraud-on-the-market theory, **10:30.10**
 Artificial inflation, fraud on the market and, **11:11**
 Auction rate securities and market manipulation, **10:31.90**
 Availability of damages, analysis, **12:12**
 Benefit of the bargain measure of damages, **13:3, 14:65**
 Causation. Loss causation, below
 Circuit courts, **10:13 et seq., 10:31 et seq., 14:1 et seq.**
 Circuit split
 fraud-created-the-market theory, **10:31 et seq.**
 liability under Rule 10b-5, **10:14 et seq.**
 Class certification, rebuttal of fraud-on-the-market theory, **10:30.15**
 Common law
 generally, **12:10**
 contribution, **20:22 to 20:24**
 fraud, loss causation, **11:7**
 Conclusion, **11:12**
 Conduct rendered unlawful by Rule 10b-5, **10:5, 10:6**
 statement makers and disclosure committees, **10:5.10**
 Congressional action, contribution, **20:15**
 Congressional intent, contribution, **20:12**
 Congressional response to Lampf, **9:16.10**
 Congressional response to Morrison decision, **10:2.60**
 Connection with purchase or sale, **10:3**
 Consequential damages. Special or consequential damages, below
 Constitutional law
 generally, **9:4 et seq.**
 aiding and abetting, **9:8**
 consequences of exercise of judicial power, **9:6**
 contribution, implied right to, **9:7**
 judicial creation and perpetuation of private right of action, **9:5, 9:6, 9:9**
 Section 27A, **9:16.10**
 uncertain origins of implied remedy, **9:4**
 Contract cases, contribution, **20:17**
 Contract model, **9:11**
 Contribution
 generally, **20:9 et seq.**
 common law, **20:22 to 20:24**
 congressional action, **20:15**
 congressional intent, **20:12**
 constitutional law, **9:7**

RULE 10b-5—Cont'd

Contribution—Cont'd
 contract cases, **20:17**
 distinction between implied and express victims' remedies, **20:25**
 fleshing out victim claim, **20:24**
 holding and analysis of Supreme Court, **20:26**
 independent federal regulatory scheme, **20:18**
 legislative scheme, **20:16**
 Northwest Airlines and Texas Industries, **20:19**
 policy considerations, **20:13**
 strongest arguments, **20:11 et seq.**
 well established right, **20:14 et seq.**
 Cover measure of damages, Tenth Circuit, **14:52**
 Definition of theories, Supreme Court, **13:2**
 Direct market repercussion theory, Second Circuit, **14:10**
 Disclosure, materiality, **10:27.60**
 Disgorgement
 generally, **14:62**
 First Circuit, **14:4**
 Second Circuit, **14:11**
 District of Columbia Circuit
 generally, **10:25, 14:57 to 14:59**
 liability under Rule 10b-5, **10:25**
 rescissionary relief, **14:58**
 valuation limits, **14:59**
 Divergent court approaches
 fraud-created-the-market theory, **10:31 et seq.**
 liability under Rule 10b-5, **10:14 et seq.**
 Dura impact on securities fraud sentences, **11:11.10**
 Duty to disclose, materiality, **10:27.60**
 Eighth Circuit
 generally, **10:21, 14:42 to 14:45**
 calculation of damages, **14:43**
 liability under Rule 10b-5, **10:21**
 materiality of misstatement or omission, **14:45**
 valuation date, **14:44**
 Election of rescission or rescissionary damages, Tenth Circuit, **14:51**
 Elements of action, **9:13**
 Eleventh Circuit
 generally, **10:24, 14:54 to 14:56**
 fraud-created-the-market theory, **10:31.30**
 liability under Rule 10b-5, **10:24**
 limitations on damages, **14:56**
 rescission, **14:55, 14:56**
 Event studies in securities fraud litigation, **25B:6**
 Express remedies, limitations from, **12:5, 12:6**
 External market forces, Seventh Circuit, **14:39**
 Fiduciary duty, breach of, **10:7**
 Fifth Circuit
 generally, **10:18, 14:23 to 14:28**
 fraud-created-the-market theory, **10:31.20**

RULE 10b-5—Cont'd

Fifth Circuit—Cont'd
 liability under Rule 10b-5, **10:18**
 limitations on general rule applicability, **14:24**
 materiality, role in damage measurement, **14:27**
 privity, **14:25**
 rescission, **14:26**
 special or consequential damages, **14:28**
 First Circuit
 generally, **10:14, 14:2 to 14:4**
 exceptions, **14:3**
 liability under Rule 10b-5, **10:14**
 unjust enrichment or engorgement, **14:4**
 Five year statute of repose, **9:19**
 Fleshing out victim claim, contribution, **20:24**
 Foreign cubed cases, extraterritorial application of Rule 10b-5, **10:2.50, 10:2.60, 27:10**
 Forfeitures, tolling, **9:20.30**
 Fourth Circuit
 generally, **10:17, 14:17 to 14:22**
 discretion, factors in applying, **14:18**
 liability under Rule 10b-5, **10:17**
 materiality of actions or omissions, **14:20**
 qualified profit measure of damages, **14:21**
 rescission, rejection of, **14:19**
 rescissionary measure of damages, **14:22**
 Fraud-created-the-market theory, **10:30**
 generally, **10:31**
 endorsement by circuit courts, **10:31.10 to 10:31.40**
 reconciling circuit split, **10:31.80**
 regulatory process, reliance on, **10:31.35**
 rejection by circuit courts, **10:31.55 to 10:31.80**
 reliance, **10:31.35**
 Fraud-on-the-market theory
 actions against analysts, **10:30.10**
 artificial inflation, **11:11**
 measure of damages, uniformity, **13:16**
 rebuttal during class certification, **10:30.15**
 Implied right to contribution. Contribution, above
 Independent federal regulatory scheme, contribution, **20:18**
 Jurisdictional means, **10:2**
 Jurisdictional model, **9:12**
 Legislative intent, materiality, **13:10, 13:11**
 Loss causation
 generally, **11:1 et seq.**
 abandonment of loss causation, **11:9**
 arguments supporting loss causation, **11:4 et seq.**
 common law fraud, **11:7**
 denial of all recovery, **11:3**
 evolution, **11:2**

RULE 10b-5—Cont'd

Loss causation—Cont'd
 life after loss causation, **11:10**
 regulatory scheme, analogies to, **11:5**
 Supreme Court declarations, **11:6**
 unlimited exposure, potential for, **11:8**
 Loss causation, fraud on the market and artificial inflation, **11:11**
 Lower courts, **10:13 et seq., 14:1 et seq.**
 Market manipulation and auction rate securities, **10:31.90**
 Materiality
 generally, **12:6 to 12:9, 13:7 et seq., 14:67**
 duty to disclose, **10:27.60**
 Eighth Circuit, **14:45**
 Fifth Circuit, **14:27**
 Fourth Circuit, **14:20**
 Ninth Circuit, **14:49**
 Second Circuit, **14:7**
 Seventh Circuit, **14:34, 14:39, 14:40**
 shareholder proposals, **10:27.80**
 statistically significant test, **10:27.50**
 the bespeaks caution doctrine, **10:27**
 Third Circuit, **14:16**
 Misappropriation, **10:11**
 Morrison, evolution of and extraterritorial reach of Rule 10b-5, **10:2.70**
 Ninth Circuit
 generally, **10:22, 14:46 to 14:49**
 calculation of value, **14:48**
 liability under Rule 10b-5, **10:22**
 materiality, quantification of, **14:49**
 rescission, **14:47**
 Objectification of culpability, **10:12**
 Out-of-pocket, Supreme Court, **13:4 to 13:6**
 Policy considerations, contribution, **20:13**
 Presumptions of reliance, **10:30**
 Private Securities Litigation Reform Act of 1995, forward looking incentives, **10:28, 10:29**
 Privity, Fifth Circuit, **14:25**
 Profits of defendant
 generally, **14:63**
 Fourth Circuit, **14:21**
 Second Circuit, **14:9**
 Third Circuit, **14:14**
 Public disclosure and materiality, Second Circuit, **14:10**
 Puffery, **10:27.70**
 Punitive damages, **14:66**
 Purpose, statute of limitations, **9:15**
 Rebuttal of fraud-on-the-market theory, **10:30.15**
 Reliance
 fraud-created-the-market theory, **10:30**
 fraud-on-the-market theory, **10:30.50, 10:31.35**

RULE 10b-5—Cont'd

Remedial powers, **12:2 to 12:4**
 Resale price measure of damages, Second Circuit, **14:8**
 Rescission
 generally, **14:64**
 District of Columbia Circuit, **14:58**
 Eleventh Circuit, **14:55, 14:56**
 Fifth Circuit, **14:26**
 Fourth Circuit, **14:19, 14:22**
 materiality, **13:12**
 Ninth Circuit, **14:47**
 Seventh Circuit, **14:35**
 Third Circuit, **14:15**
 Retroactivity, **9:16 et seq.**
 Sarbanes-Oxley Act, statutes of limitations implications, **9:16**
 Scienter, **10:6, 10:10**
 SEC investigations
 two year limitations period, **9:18.10**
 Second Circuit
 generally, **10:15, 14:5 to 14:12**
 direct market repercussion theory, **14:10**
 disgorgement, **14:11**
 exceptions, **14:6**
 extraterritorial application to foreign cubed cases, **10:2.50, 27:10**
 liability under Rule 10b-5, **10:15**
 materiality of misstatements or omissions, **14:7**
 profit of defendant, recovery of, **14:9**
 public disclosure and materiality, **14:10**
 resale price measure of damages, **14:8**
 Section 27A, constitutional law, **9:16.10**
 Section 27(a), district court jurisdiction, **12:2**
 Section 28(a) limitations on damages, **12:3, 12:4**
 Securities Act of 1933, **12:5 et seq.**
 Securities Exchange Act of 1934, **12:5 et seq.**
 Security, **10:4**
 Sentencing, Dura impact on, **11:11.10**
 Seventh Circuit
 generally, **14:32 to 14:41**
 congruence between rescissionary and market measure of damages, **14:38**
 exceptions, **14:33**
 external market forces, **14:39**
 fraud-created-the-market theory, **10:31.55**
 liability under Rule 10b-5, **10:20**
 materiality, role in damages measurement, **14:34**
 materiality of nondisclosure, quantification of, **14:39, 14:40**
 rescission, **14:35**
 Uniform Commercial Code, analogy to, **14:36, 14:37**
 Shareholder proposals, materiality, **10:27.80**

RULE 10b-5—Cont'd

Sixth Circuit
 generally, **10:19, 14:29 to 14:31**
 additional relief, **14:30**
 fraud-created-the-market theory, **10:31.70**
 liability under Rule 10b-5, **10:19**
 limitations upon recovery, **14:31**
 Special or consequential damages
 Fifth Circuit, **14:28**
 Tenth Circuit, **14:53**
 Standing, holder suits, **10:3.50**
 Statistically significant test, materiality, **10:27.50**
 Statute of limitations, **9:14 et seq.**
 Statutory guidance, **12:1 et seq.**
 Supreme Court guidance, **9:15 to 9:20.40, 13:1 et seq.**
 Tellabs case, **24:58**
 Tenth Circuit
 generally, **10:23, 14:50 to 14:52**
 consequential damages, **14:53**
 cover measure of damages, **14:52**
 election of rescission or rescissionary damages, **14:51**
 fraud-created-the-market theory, **10:31.30**
 liability under Rule 10b-5, **10:23**
 Test for implication, **9:2**
 Third Circuit
 generally, **10:16, 14:13 to 14:16**
 fraud-created-the-market theory, **10:31.60**
 liability under Rule 10b-5, **10:16**
 materiality, **14:16**
 profits of defendant, **14:14**
 rescission, **14:15**
 Threshold elements, **10:1 to 10:3**
 Tippee liability, **10:9, 10:10**
 Tipper liability, **10:8**
 Tolling, **9:20 et seq.**
 Tort law, **12:10**
 Tort model, **9:10**
 Two and five year limitations period, **9:17 et seq.**
 retroactivity, **9:17.10**
 Uniform Commercial Code, Seventh Circuit, **14:36, 14:37**
 Uniformity of measure of damages under Sections 12(2) and 10(b), **13:13 to 13:16**
 Unjust enrichment, First Circuit, **14:4**
 Valuation date, Eighth Circuit, **14:44**
 Valuation limits, District of Columbia Circuit, **14:59**
 Well established right, contribution, **20:14 et seq.**

RULE 26

Scienter, discoverability of identities of confidential witnesses, **24:54.10**

SAFE HARBOR

Private Securities Litigation Reform Act of 1995,
3:15 to 3:18

SANCTIONS

Private Securities Litigation Reform Act of 1995,
 abusive litigation, **3:19**

SARBANES-OXLEY ACT (SOX)

Generally, **5A:1 to 5A:25**

Attorney-client privilege, securities fraud, new
 statutory duty to disclose client confidences,
5C:3, 5C:5

Attorneys

conduct rules for—Section 307, **5A:12**
 disclosure of client confidences, new federal
 statutory duty, **5C:3**
 exposure, securities fraud after Sarbanes-
 Oxley, **5C:1 to 5C:9**
 nationalization consequences, **5C:9**
 nationalization of securities regulation, **5C:4**
 national securities law standards, trend toward,
5C:7
 preemptive force, SEC attorney professional
 standards, **5C:6**
 private right of action against attorney for fail-
 ure to blow whistle, **5C:8**
 securities fraud following Sarbanes-Oxley Act,
5C:1

whistleblowing, below

Audits and auditors

audit committee
 generally—Section 301, **5A:7**
 financial experts—Section 407, **5A:16**
 auditor-related provisions, **5A:22**
 improper influence on audits—Section 303,
5A:8

Automatic stay, debtor-company in bankruptcy,
5D:3

Bankruptcy and securities fraud

generally, **5D:1**
 automatic stay, **5D:3**
 claims against debtor-company while in bank-
 ruptcy, **5D:3**
 class proof of claims, **5D:4**
 discharge, excepting securities fraud claims,
5D:5
 examiners, **5D:7**
 exceptions, **5D:5**

forced sale, reorganization proceedings as,
5D:2

proof of claims, **5D:4**

reorganization proceedings as forced sale,
5D:2

time of claim, **5D:3**

trustees, **5D:6**

SARBANES-OXLEY ACT (SOX)—Cont'd

Bonuses and profits, private action for—Section
 304, **5B:5**

Breach of new withdrawal and disclosure obliga-
 tions, private actions against attorneys for,
5B:10

CEO and CFO certification requirements, **5A:3,**
5B:4

Certification

CEO and CFO certification requirements,
5A:3, 5B:4

Section 906 certification, **5A:4**

Civil actions. Private civil liability enhancement,
 below

Class proof of claims, **5D:4**

Conflict of laws, state attorney confidentiality
 standards in conflict with SEC regime, **5C:5**

Corporate responsibility re CEO and CFO certifi-
 cation of financial statements, **5B:4**

Criminal law, Act reliance on, **5A:25**

Damages

private actions—Section 803, damages not
 dischargeable, **5B:9**

Discharge, excepting securities fraud claims,
5D:5

Disclosures

attorney duty to disclose client confidences,
5C:3

disclosure report—Section 401, **5A:13, 5B:7**

private actions against attorneys for breach of
 new withdrawal and disclosure obliga-
 tions, **5B:10**

rapid and current basis, disclosure on—Section
 409, **5B:8**

real time disclosures—Section 409, **5A:18**

SEC review of disclosures—Section 408,
5A:17

Examiners, bankruptcy, **5D:7**

Excepting securities fraud claims from bank-
 ruptcy discharge, **5D:5**

Financial experts, audit committee—Section 407,
5A:16

Financial officers, ethics code—Section 406,
5A:15

Forced sale, reorganization proceedings as, **5D:2**

Forfeiture of executive payments upon restate-
 ments—Section 304, **5A:9**

Forfeitures

tolling

limitation of actions, securities fraud,
9:20.30

Improper influence on audits—Section 303, **5A:8**

Informants, no retaliation against—Section 1107,
5A:21

Insider trading

pension blackout periods, trades during—Sec-
 tion 306, **5A:11, 5B:6**

SARBANES-OXLEY ACT (SOX)—Cont'd

Insider trading—Cont'd
 professional liability under Sarbanes-Oxley, **15:6**
 Limitation of actions, securities fraud
 implied remedies, **9:15 et seq.**
 section 10(b) and SEC complaints, **9:18**
 Section 804, **5A:19, 5B:2**
 tolling, **9:20 et seq.**
 Loans to executive officers and directors, prohibition, **5A:6**
 Management assessment of internal accounting controls—Section 404, **5A:14**
 Nationalization of securities regulation, damages for attorney exposure, **5C:4**
 National securities law standards, trend toward, **5C:7**
 Officer and director bars—Section 305, **5A:10**
 Omissions from Act, **5A:24**
 Overview, **5A:2**
 Political and economic environment, **5A:1**
 Preemptive force, SEC attorney professional standards, **5C:6**
 Private civil liability enhancement generally, **5B:1 to 5B:9**
 bonuses and profits, action for, **5B:5**
 breach of new withdrawal and disclosure obligations, private actions against attorneys for, **5B:10**
 corporate responsibility re CEO / CFO certifications of financial statements, **5B:4**
 damages not dischargeable—Section 803, **5B:9**
 fraud, statute of limitations—Section 804, **5B:2**
 new, private causes of action, **5B:3**
 pension fund blackouts, insider trading during—Section 306, **5B:6**
 periodic reports, private actions based on disclosures in—Section 306, **5B:7**
 rapid and current basis, disclosure on—Section 409, **5B:8**
 statute of limitations for fraud—Section 804, **5B:2**
 Private right of action against attorneys failing to blow the whistle, **5C:8**
 Proof of claims, bankruptcy and securities fraud, **5D:4**
 Reorganization proceedings as forced sale, **5D:2**
 SEC review of disclosures—Section 408, **5A:17**
 Section 906 certification, **5A:4**
 Securities fraud
 for other aspects of securities fraud, see specific entries in this topic
 attorney exposure to damages. Damages, above

SARBANES-OXLEY ACT (SOX)—Cont'd

Securities fraud—Cont'd
 statute of limitations. Limitation of actions, above
 Shorter Section 16 reporting deadline, **5A:5**
 Significance of Act, **5A:23**
 Statute of limitations. Limitation of actions, above
 Tolling
 limitation of actions, securities fraud, **9:20 et seq.**
 Trustees, bankruptcy, **5D:6**
 Whistleblowing
 attorney exposure to damages
 federal common law duty to blow whistle in re securities fraud, **5C:2**
 private right of action, failure to blow whistle on securities fraud, **5C:8**
 whistleblower protection—Section 806, **5A:20**
 Withdrawal, private actions against attorneys for breach of new withdrawal and disclosure obligations, **5B:10**

SCIENTER

Availability of work-product protection, **24:54.20**
 Collective scienter, **24:55**
 Confidential sources
 circuit survey, **24:53.10**
 discovery, **24:54, 24:54.10**
 documents from, **24:53.20**
 pleading, **24:52.50, 24:53, 24:55**
 private investigators, **24:53.30**
 Rule 26 discoverability of identities, **24:54.10**
 Core operations inference
 generally, **24:56**
 allegations, bolstering with core operations inference, **24:56.20**
 imputing scienter on core operations inference alone, **24:56.10**
 misconstruing inference, **24:56.40**
 reconciling approaches, **24:56.50**
 Inference, core operations, **24:56 et seq.**
 Obtaining order of protection, **24:54.30**
Private Securities Litigation Reform Act of 1995 (this index)
 Red flags, **24:6**
 Rule 10b-5, **10:6, 10:10**
 Rule 26 discoverability of identities of confidential witnesses, **24:54.10**
 Tellabs analysis
 availability of work-product protection, **24:54.20**
 circuit survey, use of confidential witnesses, **24:53.10**
 collective scienter, **24:55**
 discovery of confidential witnesses, **24:54, 24:54.10**

SCIENTER—Cont'd

Tellabs analysis—Cont'd
 establishing, 24:52
 Fifth Circuit, 24:10
 First Circuit, 24:8
 obtaining order of protection, 24:54.30
 pleading, 24:4, 24:7 to 24:11, 24:52.50, 24:53, 24:55
 protection order, 24:54.30
 Rule 26 discoverability of identities of confidential sources, 24:54.10
 Seventh Circuit, 24:11
 Third Circuit, 24:9
 use of confidential witnesses, 24:53, 24:53.10
 work-product protection, 24:54.20
 Work-product protection, 24:54.20

SCOPE OF FEDERAL SECURITIES REGULATION

Generally, 5:1 to 5:15
 Internet
 electronic delivery, 5:14
 securities fraud, 5:15
 Preemptive course, 5:1
Securities Litigation Uniform Standards Act of 1998 (this index)

SECONDARY LIABILITY

Insider trading. See **Insider Trading** (this index)

SECTION 10(b), SECURITIES EXCHANGE ACT OF 1934

Event studies, 25B:6
 Insider trading, Stoneridge decision, 15:12
 Instructions to jury. See **Instructions to Jury** (this index)
 Statutes of limitations, 9:18
 Tellabs case, 24:58

SECTION 11, SECURITIES ACT OF 1933

Generally, 6:1 et seq.
 Causation defense, lack of, 6:25
 Common law remedies, inadequacy of, 6:7
 Declining market, 6:21
 Defenses, 6:4
 Elements of liability, 6:3
 Event studies, 25B:8
 False statement of opinion, pleading under Section 11, 6:3.20
 Forced seller doctrine and Section 11 claims, 14A:2
 Formula for damages
 generally, 6:9 et seq.
 amended formula, 6:11
 criticism, 6:9
 original formula, 6:10
 plaintiff keeps security, 6:12
 plaintiff sells security before suit, 6:13

SECTION 11, SECURITIES ACT OF 1933**—Cont'd**

Formula for damages—Cont'd
 plaintiff sells security during suit, 6:14
 summary of damage alternatives, 6:15 to 6:18
 value, 6:17, 6:18
 Good will, misrepresentation in registration statements, 14A:1
 Influenced market, 6:23
 Instructions to jury
 generally, 24:35 et seq.
 limit on recovery, 24:40
 plaintiff retains stock, 24:36
 plaintiff sells security before suit, 24:37
 plaintiff sells security during litigation, 24:38
 special interrogatories, 24:41
 underwriter, defendant as, 24:39
 Legislative history of civil remedies, 6:6
 Liability, generally, 6:2 to 6:4.10
 Loan loss reserves, misrepresentation in registration statements, 14A:1
 Loss causation, 11A:18, 11A:19, 12:5.05
 Make plaintiff whole, 6:20
 Misrepresentation of good will and loan loss reserves in registration statements, 14A:1
 Mutual funds, fraud against, 6:4.10
 Negative causation, proof of, 6:28
 Overview of violations, 6:2 et seq.
 Prospectus
 forced seller doctrine and Section 12 claims, 14A:2
 material misrepresentations, private action, 14A:2
 private action for material misrepresentations, 14A:2
 Proviso for damages
 generally, 6:25 et seq.
 causation defense, lack of, 6:25
 conclusion, 6:30
 judicial guidance, 6:27
 judicial restraints, 6:29
 negative causation under Section 11, 6:28, 6:31
 proof of negative causation, 6:28
 value, 6:26
 Purposes of civil remedies, 6:5 to 6:8
 Registration statements
 good will, misrepresentation, 14A:1
 loan loss reserves, misrepresentation, 14A:1
 Rising market, 6:22
 Special interrogatories, 24:41
 Summary of damage alternatives, 6:15 to 6:18
 Supplement to common law, design as, 6:8
 Theory of damages
 generally, 6:19 et seq.
 contrast with traditional damage formula, 6:19

SECTION 11, SECURITIES ACT OF 1933**—Cont'd**

Theory of damages—Cont'd
 damage alternatives, **6:24**
 declining market, **6:21**
 influenced market, **6:23**
 make plaintiff whole, **6:20**
 rising market, **6:22**

Underwriters (this index)

Value, **6:17, 6:18, 6:26**

SECTION 12, SECURITIES ACT OF 1933

Forced seller doctrine and Section 12 claims, **14A:2**
 Good will, misrepresentation in registration statements, **14A:1**
 Instructions to jury, **24:42 to 24:44**
 Loan loss reserves, misrepresentation in registration statements, **14A:1**
 Loss causation, **11A:19, 12:5:05**
 Misrepresentation of good will and loan loss reserves in registration statements, **14A:1**
 Prospectus
 forced seller doctrine and Section 12 claims, **14A:2**
 material misrepresentations, private action, **14A:2**
 private action for material misrepresentations, **14A:2**
 Registration statements
 good will, misrepresentation, **14A:1**
 loan loss reserves, misrepresentation, **14A:1**

SECTION 16, SECURITIES EXCHANGE ACT OF 1934

Generally, **8:6 et seq.**
 Dividends, **8:11**
 Employee stock options, **8:10**
 Expenses, **8:13**
 Interest, **8:12**
 Matching, tracing, and pairing, **8:9**
 Measure of damages, **8:8**
 Purchase or sale price in noncash transactions, **8:14**
 Statute of limitations, **8:14.50**

SECTION 17(A)

Implied actions and remedies, **19:1, 19:2**

SECTION 27A

Rule 10b-5, constitutional law, **9:16.10**

SECTION 27(A)

Rule 10b-5, district court jurisdiction, **12:2**

SECTION 28(A)

Rule 10b-5, limitations on damages, **12:3, 12:4**

SECURITIES ACT OF 1933

Generally, **App 1**
 Rule 10b-5. See **Rule 10b-5** (this index)
 Section 11, Securities Act of 1933. See **Section 11, Securities Act of 1933** (this index)
 Section 12, Securities Act of 1933. See **Section 12, Securities Act of 1933** (this index)

SECURITIES AND EXCHANGE COMMISSION

Aiding and abetting enforcement actions, effect of Stoneridge decision, **15:17**
 Complaints, Sarbanes-Oxley Act Section 10(b), **9:16**
 Sarbanes-Oxley Act, SEC review of disclosures—Section 408, **5A:17**

SECURITIES EXCHANGE ACT OF 1934

Generally, **8:1 et seq., App 2**
 Causation, **8:4, 8:16**
 Listed stock manipulations, **8:3 to 8:5**
 Misstatement in filed reports, **8:15, 8:16**
 Overview of act, **8:2**
 Rule 10b-5. See **Rule 10b-5** (this index)
 Section 9(e), **8:3 to 8:5**
 Section 10(b), Securities Exchange Act of 1934. See **Section 10(b), Securities Exchange Act of 1934** (this index)
 Section 16, Securities Exchange Act of 1934. See **Section 16, Securities Exchange Act of 1934** (this index)
 Section 18, **8:15, 8:16**

SECURITIES FRAUD

Confidential witnesses, pleading, **24:53**
Sarbanes-Oxley Act (SOX) (this index)

SECURITIES FRAUD HISTORIC CAUSATION REQUIREMENT

Racketeer influenced and corrupt organizations, **22:4**

SECURITIES FRAUD LITIGATION

Event studies, **25B:1 et seq.**

SECURITIES LITIGATION UNIFORM STANDARDS ACT OF 1998

Generally, **5:2 to 5:13**
 Amendment by plaintiff, **5:10**
 Best execution claims, **5:8.30**
Class Actions (this index)
 Covered securities, **5:7**
 Direct rather than derivative actions, **5:8**
 Discovery stay, **5:13**
 Dismissal, **5:9**
 Federal class actions in state court, **5:8.70**
 Language of act, **5:3**
 Plaintiff ability to amend, **5:10**
 Preclusion, **5:4 to 5:8.70**

SECURITIES LITIGATION UNIFORM STANDARDS ACT OF 1998—Cont'd
Procedural devices, **5:11 to 5:13**
Removal, **5:12**
Scope of Federal Securities Regulation (this index)
Scope of preclusion, **5:4 to 5:8.70**

SECURITY
Class actions, security for costs, **25:5**
Defined, **1:5**
Laws, generally, **1:3**
Rule 10b-5, **10:4**

SELECTION OF INTERIM LEAD PLAINTIFF
Advertising investigations, solicit lead plaintiffs, **25:1.40**
Monitoring arrangements, institutional investors, **25:1.30**
Pay to play arrangements, **25:1.20**

SELF-REGULATORY ORGANIZATIONS (SROs)
Enforcement of securities laws, role of SROs, **26A:2**
FINRA and the role of SROs in enforcement of securities laws, **26A:2**

SENTENCING
Rule 10b-5, **11:11.10**

SETTLEMENT
Class actions, **25:2, 25:3**
Contribution, effect on, **20:5, 20:27**
Independent approval, **25:3.10**
Non-lead counsel, issues with and other actors seeking payment from the common fund, **25:4.40**
Private Securities Litigation Reform Act of 1995 (this index)

SEVENTH AMENDMENT
Event studies in securities fraud litigation, **25B:2**

SPECIAL DAMAGES
Rule 10b-5. See **Rule 10b-5** (this index)

SPECIAL INTERROGATORIES
Section 11, Securities Act of 1933, **24:41**

STANDING
Rule 10b-5, holder suits, **10:3.50**

STATE COURTS
Federal class actions in state court, **5:8.70**
Insider trading, Stoneridge decision, **15:19**

STATE-LAW RICO EQUIVALENTS
Racketeer influenced and corrupt organizations, **22:8**

STATE OF MIND
Private Securities Litigation Reform Act of 1995, pleadings, **3:10**

STATISTICALLY SIGNIFICANT
Rule 10b-5, materiality test, **10:27.50**

STATISTICS
Class actions under PSLRA, NERA and cornerstone research, **4:3**

STATUTE OF LIMITATIONS
Limitation of actions. See **Limitation of Actions** (this index)

STONERIDGE CASE
Insider Trading (this index)

SUBROGATION
Generally, **26:1, 26:3**

SUMMARY EXHIBITS
Instructions to jury, **24:26, 24:27**

SUMMARY JUDGMENT
Generally, **24:17**
Event studies in securities fraud litigation, **25B:9**

SUPREME COURT
Insider Trading (this index)
Material facts, statistical significance, **18:5**
Private Securities Litigation Reform Act of 1995 (this index)
Rule 10b-5, **9:15 to 9:20.40**

SWAPS
Credit default swaps under FINRA rules, **26A:1**
Dodd-Frank, antifraud measures, **5E:2**

TELLABS CASE
Allegations, PSLRA, **3:11.10**
Circuit survey, use of confidential witnesses, **24:53.10**
Collective scienter, **24:55**
Confidential sources and pleading, **24:52.50 et seq.**
Discovery and confidential sources, **24:54, 24:54.10**
Establishing scienter, **24:52**
Expansion beyond § 10b and Rule 10b-5 actions, **24:58**
Fraud by hindsight, **24:57**
Group pleading, **24:55**
Motive, pleading scienter, **24:52.50**
Opportunity, pleading scienter, **24:52.50**
Private Securities Litigation Reform Act of 1995, **3:11.05, 3:11.10**
Recklessness, pleading scienter, **24:52.50**
Rule 10b-5, **24:58**

TELLABS CASE—Cont'd

Scienter
 availability of work-product protection, **24:54.20**
 circuit survey, use of confidential witnesses, **24:53.10**
 collective scienter, **24:55**
 confidential witnesses, **24:53, 24:53.10**
 core operations inference, **24:56 et seq.**
 discovery of confidential witnesses, **24:54, 24:54.10**
 establishing, **24:52**
 Fifth Circuit, **24:10**
 First Circuit, **24:8**
 incorporation by reference, **3:11.152**
 inference, core operations, **24:56 et seq.**
 judicial notice, **3:11.152**
 motive, pleading scienter, **24:52.50**
 obtaining order of protection, **24:54.30**
 opportunity, pleading scienter, **24:52.50**
 pleading scienter, **24:4, 24:7 to 24:11, 24:52, 24:52.50, 24:55**
 protection order, **24:54.30**
 recklessness, pleading scienter, **24:52.50**
 Rule 26 discoverability of identities of confidential sources, **24:54.10**
 Seventh Circuit, **24:11**
 Third Circuit, **24:9**
 work-product protection, **24:54.20**
 Section 10(b) of Securities Exchange Act of 1934, **24:58**
 Supreme Court, guidance on pleading scienter, **3:11.05**

TENDER OFFERS

Interference with market for corporate control, **16:3, 16:4**

THE CRIMINAL CONVICTION EXCEPTION

Racketeer influenced and corrupt organizations, **22:7**

THIRD CIRCUIT TASK FORCE

Class actions, **25:7**

TIPPEE LIABILITY

Rule 10b-5, **10:9, 10:10**

TIPPER LIABILITY

Rule 10b-5, **10:8**

UNDERWRITERS

Actions against, **6:3.10, 24:39**
 Liability for shares distributed to public, **6:32**
 Section 11, Securities Act of 1933, **6:3.10, 6:32, 24:39**

UNIFORM COMMERCIAL CODE

Rule 10b-5, Seventh Circuit, **14:36, 14:37**

UNJUST ENRICHMENT

Rule 10b-5, First Circuit, **14:4**

VALUE

Rule 10b-5, **14:44, 14:59**
 Section 11, Securities Act of 1933, **6:17, 6:18, 6:26**

WHISTLEBLOWING

Dodd-Frank, **5E:3**
Sarbanes-Oxley Act (SOX) (this index)

WITNESSES

Confidential, securities fraud pleadings, **24:53**

WORK-PRODUCT PROTECTION

Scienter, **24:54.20**